By: Jared Kaltwasser
Chimeric antigen receptor-based immunotherapies show promise when directed at viral targets, but data are limited.
Jared Kaltwasser is a freelance writer for The American Journal of Managed Care® (AJMC®). He specializes in medicine and healthcare, with a focus on topics such as dermatology, endocrinology, gene therapy, and oncology, while also covering healthcare technology and pharmaceutical regulation. Jared's work has been featured in various publications including Contagion_Live, Medical Economics, and Cancer Network.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .